Mon, October 31, 2022

William Maughan Maintained (YMAB) at Strong Buy with Decreased Target to $27 on, Oct 31st, 2022

William Maughan of Canaccord Genuity, Maintained "Y-mAbs Therapeutics, Inc." (YMAB) at Strong Buy with Decreased Target from $35 to $27 on, Oct 31st, 2022.

William, nor any peers, have made any analyst calls on YMAB in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30